85P Tislelizumab combined with apatinib and oxaliplatin plus S1 as neoadjuvant therapy for Borrmann IV large Borrmann III type and bulky N positive advanced gastric cancer: A single-arm multicenter trial (TAOS-3B-Trial). (December 2022) - Chen, L.; Ye, Z.; Liu, G.; Lin, Q.; Chi, Y.; Wang, J.; Wei, S.; Wei, C.; Liu, S.; Zeng, Y.; Chen, S.; Wang, Y.